Additional file 1 of Immune checkpoint inhibitors in cancer: the increased risk of atherosclerotic cardiovascular disease events and progression of coronary artery calcium
Creators: name: Gong, Bingxin
name: Guo, Yusheng
name: Li, Yi
name: Wang, Jing
name: Zhou, Guofeng
name: Chen, Yong-hao
name: Nie, Tong
name: Yang, Ming
name: Luo, Kun
name: Zheng, Chuansheng
name: Pan, Feng
name: Liang, Bo
name: Yang, Lian
Publisher: name: figshare
Year: 2024
Subjects: subject: Medicine
subject: Physiology
subject: FOS: Biological sciences
subject: Pharmacology
subject: Chemical Sciences not elsewhere classified
subject: Sociology
subject: FOS: Sociology
subject: Biological Sciences not elsewhere classified
subject: Cancer
subject: Mental Health

description: Additional file 1: Table S1. Baseline laboratory values of patients in ASCVD events study before and after PSM. Table S2. Univariate and Multivariate Cox proportional hazards analyses of ASCVD events before PSM. Table S3. Univariate and Multivariate Cox proportional hazards analyses of ASCVD events with blood lipids before PSM. Table S4. Univariate and Multivariate Cox proportional hazards analyses of ASCVD events with blood lipids after PSM. Table S5. Univariate and Multivariate Cox proportional hazards analyses of ASCVD events with the cycles of ICI. Table S6. Univariate and Multivariate Cox proportional hazards analyses of ASCVD events with EGFR, ALK and KRAS. Table S7. The survival rate of patients with and without ASCVD events before and after PSM. Table S8. Baseline characteristics of patients in imaging study before and after PSM. Table S9. Baseline laboratory values of patients in imaging study before and after PSM. Table S10. CAC volume and score in the ICI and the Non-ICI group at four time points before PSM. Table S11. CAC volume and score in the ICI and the Non-ICI group at four time points after PSM. Table S12. Progression of CAC volume and score Between the ICI and the Non-ICI Group at 12 Months before PSM. Table S13. Number of patients with different CAC score grade in the ICI and the Non-ICI group before and after PSM. Table S14. CAC score grade progression in the ICI and the Non-ICI group before and after PSM. Table S15. Multiple linear regression analysis for associations of ICIs with absolute volume progression, absolute score progression, relative volume progression and relative score progression of CAC at 12 months before PSM. Fig. S1. Representative axial CT images show the progression of CAC volume and score in patients with and without ICI therapy. Fig. S2. Kaplan–Meier curves of the cumulative incidence of the ASCVD events between the ICI and the non-ICI group before PSM. Fig. S3. Forest plot of the hazard ratios for the total ASCVD event stratified by different subgroups before PSM. Fig. S4. Forest plot of the hazard ratios for the total ASCVD event stratified by different subgroups after PSM. Fig. S5. Bean plots show time-course progression of the CAC volume and score between the ICI and the non-ICI group before PSM. Fig. S6. Heatmap of CAC progression in each segment of the coronary artery before (A) and after (B) PSM. Fig. S7. Stacked bar graphs of CAC grade progression in ICI (A) and non-ICI (B) group before PSM and in ICI (C) and non-ICI (D) group after PSM. Fig. S8. Scatter plots of cycles of ICI versus absolute volume progression, absolute score progression, relative volume progression and relative score progression of CAC at 12 months before (A-D) and after (E–H) PSM.